-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case
With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Raffles Medical Group (SGX:BSL). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
See our latest analysis for Raffles Medical Group
How Fast Is Raffles Medical Group Growing?
The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Raffles Medical Group managed to grow EPS by 15% per year, over three years. That's a pretty good rate, if the company can sustain it.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The music to the ears of Raffles Medical Group shareholders is that EBIT margins have grown from 15% to 19% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
SGX:BSL Earnings and Revenue History September 14th 2022While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Raffles Medical Group?
Are Raffles Medical Group Insiders Aligned With All Shareholders?
Investors are always searching for a vote of confidence in the companies they hold and insider buying is one of the key indicators for optimism on the market. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. However, small purchases are not always indicative of conviction, and insiders don't always get it right.
One gleaming positive for Raffles Medical Group, in the last year, is that a certain insider has buying shares with ample enthusiasm. Specifically, in one large transaction Executive Chairman & CEO Choon Yong Loo paid S$1.8m, for stock at S$1.19 per share. Seeing such high conviction in the company is a huge positive for shareholders and should instil confidence in their mission.
Along with the insider buying, another encouraging sign for Raffles Medical Group is that insiders, as a group, have a considerable shareholding. We note that their impressive stake in the company is worth S$330m. That equates to 13% of the company, making insiders powerful and aligned with other shareholders. Looking very optimistic for investors.
Is Raffles Medical Group Worth Keeping An Eye On?
As previously touched on, Raffles Medical Group is a growing business, which is encouraging. Better yet, insiders are significant shareholders, and have been buying more shares. That makes the company a prime candidate for your watchlist - and arguably a research priority. Of course, identifying quality businesses is only half the battle; investors need to know whether the stock is undervalued. So you might want to consider this free discounted cashflow valuation of Raffles Medical Group.
There are plenty of other companies that have insiders buying up shares. So if you like the sound of Raffles Medical Group, you'll probably love this free list of growing companies that insiders are buying.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投資一家能夠扭轉命運的公司所帶來的興奮,對一些投機者來説是一個巨大的吸引力,因此,即使是沒有收入、沒有利潤、業績不佳的公司,也能設法找到投資者。有時,這些故事可能會矇蔽投資者的頭腦,導致他們以自己的情緒投資,而不是投資於良好的公司基本面。一家虧損的公司還沒有用盈利來證明自己,最終外部資本的流入可能會枯竭。
因此,如果這種高風險和高回報的想法不適合,你可能會對盈利的、成長型的公司更感興趣,比如萊佛士醫療集團(新加坡證券交易所代碼:BSL)。現在,這並不是説該公司提供了最好的投資機會,但盈利能力是商業成功的關鍵組成部分。
查看我們對萊佛士醫療集團的最新分析
萊佛士醫療集團的增長速度有多快?
市場在短期內是一臺投票機,但從長期來看是一臺稱重機,所以你可以預期股價最終會跟隨每股收益(EPS)的結果。因此,有經驗的投資者在進行投資研究時密切關注公司每股收益是合理的。萊佛士醫療集團設法在三年內以每年15%的速度增長每股收益。這是一個相當不錯的比率,如果公司能夠維持下去的話。
營收增長是一個很好的指標,表明增長是可持續的,再加上高息税前利潤(EBIT)利潤率,這是一家公司在市場上保持競爭優勢的絕佳方式。萊佛士醫療集團股東的音樂是,在過去12個月中,息税前利潤從15%增長到19%,收入也呈上升趨勢。這兩個都是衡量潛在增長的很好的指標。
下面的圖表顯示了該公司的利潤和收入是如何隨着時間的推移而變化的。點擊圖表查看確切的數字。
新交所:BSL收益和收入歷史2022年9月14日雖然我們活在當下,但毫無疑問,在投資決策過程中,未來是最重要的。那麼,為什麼不查看這張為萊佛士醫療集團描繪未來每股收益估計的互動圖表呢?
萊佛士醫療集團內部人士是否與所有股東一致?
投資者總是在尋求對他們持有的公司投下信任票,而內幕購買是市場樂觀的關鍵指標之一。這是因為內幕收購往往表明,那些與公司關係最密切的人相信股價會有良好的表現。然而,小額收購併不總是表明堅定的信念,內部人士也不總是正確的。
去年,對萊佛士醫療集團來説,一個閃亮的積極因素是,某個內部人士懷着充分的熱情購買股票。具體地説,在一筆大型交易中,執行主席兼首席執行官崔永路以每股1.19新元的價格收購了180萬新元的股票。看到對公司如此高的信心,對股東來説是一個巨大的積極因素,應該會讓他們對自己的使命充滿信心。
除了內部人士收購,萊佛士醫療集團的另一個令人鼓舞的跡象是,內部人士作為一個集團擁有相當大的股份。我們注意到,他們在該公司令人印象深刻的股份價值3.3億新元。這相當於公司13%的股份,這讓內部人士變得強大,並與其他股東結盟。看起來對投資者來説非常樂觀。
萊佛士醫療集團值得關注嗎?
正如前面提到的,萊佛士醫療集團是一項不斷增長的業務,這是令人鼓舞的。更好的是,內部人士是大股東,他們一直在買入更多股票。這使該公司成為你觀察名單的首選--也可以説是研究重點。當然,識別優質企業只是成功的一半;投資者需要知道股票是否被低估了。所以你可能會考慮這個免費萊佛士醫療集團現金流貼現估值。
還有很多其他公司讓內部人士買進股票。所以,如果你喜歡萊佛士醫療集團的聲音,你可能會喜歡這個免費內部人士正在收購的成長型公司名單。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧